© Springer-Verlag London Ltd. 2017Hugues Duffau (ed.)Diffuse Low-Grade Gliomas in Adults10.1007/978-3-319-55466-2_27 27. Functional Rehabilitation in Patients with DLGG Guillaume Herbet1, 2, 3 and Sylvie Moritz-Gasser1, 2, 4, 3 (1) National Institute for Health and Medical Research…
Fig. 26.1 Proton radiotherapy plan (left) compared to a photon plan with IMRT (right). The proton plan demonstrates decreased low dose spill (green and blue colorwash) compared to the IMRT…
Year Authors and journal N Tumor type Contrast enhancement (%) Prior RT (%) Prior CT (%) Chemotherapy regimen Response rate CR + PR/MR (%) One year PFS (%) Median PFS…
Fully validated in clinical trials • Age >40 years • Presence of neurological deficits and/or absence of seizures at onset • Low performance status (Karnofsky <70) • Preoperative tumor diameter >4–6 cm • Astrocytoma as…
© Springer-Verlag London Ltd. 2017Hugues Duffau (ed.)Diffuse Low-Grade Gliomas in Adults10.1007/978-3-319-55466-2_13 13. Quality of Life in Patients with Diffuse Low-Grade Glioma Martin Klein1 (1) Department of Medical Psychology, VU University Medical Center, De Boelelaan 1118,…
Fig. 5.1 Three examples (a = case 1; b = case 2; c = case 3) of microfoci of “intermediate grade” at low magnification (left) and at high magnification (right)…
Molecular markers Prevalence (n > 1000 glioma subjects) (%) IDH mutation only 45 Triple-positive [TERTp-mut, IDH-mut, 1p/19q codeletion] 29 TERTp-mutation only 10 Triple negative [TERTp- wild type, IDH-wild type, 1p/19q…
Fig. 7.1 (a) Photograph of a grade II diffuse glioma culture maintained 2 weeks after resection. (b) Detection of cells expressing the mutated form of IDH1 with R132H specific antibody….
© Springer-Verlag London Ltd. 2017Hugues Duffau (ed.)Diffuse Low-Grade Gliomas in Adults10.1007/978-3-319-55466-2_1 1. Introduction: From the Inhibition of Dogmas to the Concept of Personalized Management in Patients with Diffuse Low-Grade Gliomas Hugues Duffau1, 2 (1) Department…
Type-1 Type-2 Type-3a Type-3b Clinical characteristics Age, median (IQR), y 45 (36–54) 36 (30–44) 43 (28–49) 57 (46–64) OS, mean (95% CI), y 16.38 (14.15–NA) 7.88 (6.76–9.70) 9.13 (5.05–NA)…
